Neoantigen Derived DCs as Cancer Treatment

NCT05767684 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Refractory Tumor
Solid Tumor

Interventions

BIOLOGICAL: Dendritic Cell Vaccine
DRUG: Lenvatinib
DRUG: Nivolumab

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]